Method
What have THCV trials tested?
THCV has been tested in people, with no positive primary result so far. A metabolic pilot in 62 adults with type 2 diabetes (5 mg twice daily for 13 weeks) did not move its primary HDL endpoint, although some secondary glucose measures shifted. A larger Phase 2 trial (NCT02053272, 207 participants, 2, 5 or 15 mg twice daily for 12 weeks) completed in 2016 and has no posted results. CBG Atlas records both, and Peregrine reports them as they stand.
| Pilot n=62 | NCT02053272 | |
|---|---|---|
| n | 62, type 2 diabetes | 207 listed |
| Dose | 5 mg BID, 13 weeks | 2 / 5 / 15 mg BID, 12 weeks |
| Primary | HDL, unaffected | HbA1c; results never posted |
| Peregrine | Not our trial | Not our trial |
Origin
The details come from the CBG Atlas THCV monograph. Destination law applies to every THCV inquiry.
Established
- Pilot metabolic RCT exists; primary HDL unaffected.
- NCT02053272 completed; results unpublished in the public record Atlas cites.
Not yet
- Approved use for diabetes or weight.
- A human dose at which THCV switches from CB1 antagonist to agonist; the mouse intravenous data does not establish one.
Questions
Did THCV lower blood sugar?
The pilot reported movement in some secondary glucose measures, but its primary endpoint, HDL, was unaffected. We report the primary result first and do not lead with the secondaries.
Evidence language follows CBG Atlas (Peregrine-funded; editorial independence). Not medical advice. Not a disease claim.
Related
Educational, not medical advice. Nothing here diagnoses, treats, cures or prevents any disease. Wholesale isolates are ingredients, not finished supplements. Education is aligned with CBG Atlas, which Peregrine funds without editorial control.